Low dose, oral epsilon aminocaproic acid for renal papillary necrosis and massive hemorrhage in hemoglobin SC disease

Alexander Gabrovsky, Abimbole Aderinto, Melissa Spevak, Elliot Vichinsky, Linda M.S. Resar

Research output: Contribution to journalArticle

Abstract

Renal papillary necrosis in sickling hemoglobinopathies can lead to significant complications, including hemorrhage, obstruction, and infection. Despite its frequency, there are limited therapies for protracted hemorrhage. In the past, massive hemorrhage was managed with nephrectomy. Here, we report a patient with hemoglobin SC disease and prolonged, life-threatening hemorrhage from papillary necrosis successfully treated with oral, low-dose epsilon aminocaproic acid (EACA). Although further study is warranted, this case illustrates the need to consider EACA in the conservative management of renal papillary necrosis and significant hemorrhage in sickle cell hemoglobinopathies.

Original languageEnglish (US)
Pages (from-to)148-150
Number of pages3
JournalPediatric Blood and Cancer
Volume54
Issue number1
DOIs
StatePublished - Jan 1 2010

Keywords

  • Epsilon aminocaproic acid (Amicar®)
  • Hemoglobin SC
  • Hemorrhage
  • Papillary necrosis

ASJC Scopus subject areas

  • Pediatrics, Perinatology, and Child Health
  • Hematology
  • Oncology

Fingerprint Dive into the research topics of 'Low dose, oral epsilon aminocaproic acid for renal papillary necrosis and massive hemorrhage in hemoglobin SC disease'. Together they form a unique fingerprint.

  • Cite this